Extended Paxlovid Treatment Reduces Viral Rebound in Immunocompromised COVID-19 Patients

A phase 2 trial led by Pfizer查看公司主页 suggests that extending the antiviral regimen of nirmatrelvir查看药品详情–ritonavir查看药品详情 (Paxlovid查看药品详情) beyond the standard 5-day course may help reduce the risk of viral rebound in immunocompromised individuals with COVID-19 (搜索)搜索该疾病, though longer treatment durations did not significantly improve overall viral suppression rates.

Edward Weinstein, MD, who leads Antivirals in Global Product Development at Pfizer查看公司主页 and author for the study, emphasized the potential clinical relevance of the findings. "The results from this study have implications for the clinical management of the overall immunocompromised and the severely immunocompromised populations, who are at high risk of prolonged infection leading to viral resistance and poor clinical outcomes, and for whom little guidance is available regarding optimal dosing of treatments for COVID-19 (搜索)搜索该疾病," Weinstein said.

Study Design and Patient Population

The placebo-controlled, randomized, double-blind trial, known as EPIC-IC, enrolled 156 non-hospitalized, symptomatic COVID-19 (搜索)搜索该疾病 patients aged 12 and older who were immunocompromised. Conducted across 73 sites in nine countries, participants were randomly assigned to receive Paxlovid查看药品详情 (300 mg nirmatrelvir查看药品详情 + 100 mg ritonavir查看药品详情, orally twice daily) for either 5, 10, or 15 days.

The primary endpoint measured the proportion of participants who maintained SARS-CoV-2 (搜索)搜索该疾病 RNA levels below the lower limit of quantification in nasopharyngeal swabs (2·0 log₁₀ copies/mL) from day 15 to day 44.

Efficacy Results

Sustained viral suppression was achieved in:

• 61.5% (95% CI 48.3–74.8) of participants in the 5-day group
• 70.8% (95% CI 58–83.7) in the 10-day group
• 66% (95% CI 52.9–79.1) in the 15-day group

Though differences in the primary endpoint were not statistically significant, extended courses showed a sharp drop in viral rebound rates:

• 17.3% (95% CI 8.2–30.3) in the 5-day group
• 2.1% (95% CI .1–11.1) in the 10-day group
• 2% (95% CI .1–10.6) in the 15-day group

Clinical Implications for High-Risk Patients

Weinstein noted that this reduction in viral rebound may offer added value for certain high-risk patients. "A post-hoc analysis suggested that extending Paxlovid查看药品详情 treatment beyond 5 days might improve time to SARS-CoV-2 (搜索)搜索该疾病 viral clearance for patients with severe immunocompromise," he said. "That said, additional studies are needed to confirm whether extended Paxlovid treatment durations might better control viral load and rebound risk compared with the standard 5-day treatment course among severely immunocompromised patients."

Safety Profile

Adverse events were reported in:

• 52.8% of participants in the 5-day group
• 66.7% in the 10-day group
• 60.8% in the 15-day group

Most side effects were manageable, and only two COVID-19 (搜索)搜索该疾病-related hospitalizations occurred, both in the 5-day group.

Despite the promising signals, Weinstein emphasized that the 5-day course remains appropriate for many. "For most immunocompromised patients, the approved 5-day course of Paxlovid查看药品详情 treatment is likely to promote sustained viral clearance and sufficiently control disease progression."

Future Research Directions

To better define optimal treatment duration, Pfizer查看公司主页 is advancing further research through the ASPIRE-IC trial (ClinicalTrials.gov Identifier: NCT07013474查看临床试验), which aims to explore antiviral strategies for severely immunocompromised patients with symptomatic COVID-19 (搜索)搜索该疾病.

Weinstein concluded, "We would welcome additional studies to confirm whether extended Paxlovid查看药品详情 treatment durations might better control viral load and rebound risk compared with the standard 5-day treatment course among severely immunocompromised patients."